Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tohru Ohmori
Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Responses to Crizotinib Can Occur in C-Met Overexpressing Nonsmall Cell Lung Cancer After Developing EGFR-TKI Resistance
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-12 a Lung Adenocarcinoma With Concomitant EGFR and De Novo MET Amplification Response Well to Combination of TKI and Bevacizumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Post-Progression Survival After EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
PLoS ONE
Multidisciplinary
P3.01-24 the Importance to Switch From EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
